Amicus Theraputics downgraded to Underperform from Neutral at Wedbush Wedbush downgraded Amicus following the Fabry Ph III study failure. Price target lowered to $1.50 from $6.
News For FOLD From The Last 14 Days
Check below for free stories on FOLD the last two weeks.